These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 35403085)

  • 21. Unravelling high-affinity binding compounds towards transmembrane protease serine 2 enzyme in treating SARS-CoV-2 infection using molecular modelling and docking studies.
    M P; Reddy GJ; Hema K; Dodoala S; Koganti B
    Eur J Pharmacol; 2021 Jan; 890():173688. PubMed ID: 33130280
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In silico study on spice-derived antiviral phytochemicals against SARS-CoV-2 TMPRSS2 target.
    Yadav PK; Jaiswal A; Singh RK
    J Biomol Struct Dyn; 2022; 40(22):11874-11884. PubMed ID: 34427179
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacoinformatics-based identification of transmembrane protease serine-2 inhibitors from Morus Alba as SARS-CoV-2 cell entry inhibitors.
    Shakya A; Chikhale RV; Bhat HR; Alasmary FA; Almutairi TM; Ghosh SK; Alhajri HM; Alissa SA; Nagar S; Islam MA
    Mol Divers; 2022 Feb; 26(1):265-278. PubMed ID: 33786727
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Repositioning Therapeutics for SARS-CoV-2: Virtual Screening of Plant-based Anti-HIV Compounds as Possible Inhibitors against COVID-19 Viral RdRp.
    Murali M; Gowtham HG; Ansari MA; Alomary MN; Alghamdi S; Almehmadi M; Singh SB; Shilpa N; Aiyaz M; Kalegowda N; Ledesma AE; Amruthesh KN
    Curr Pharm Des; 2022; 28(12):969-980. PubMed ID: 35796443
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mechanistic Aspects of Medicinal Plants and Secondary Metabolites against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Malekmohammad K; Rafieian-Kopaei M
    Curr Pharm Des; 2021; 27(38):3996-4007. PubMed ID: 34225607
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of novel TMPRSS2 inhibitors against SARS-CoV-2 infection: a structure-based virtual screening and molecular dynamics study.
    Manandhar S; Pai KSR; Krishnamurthy PT; Kiran AVVVR; Kumari GK
    Struct Chem; 2022; 33(5):1529-1541. PubMed ID: 35345416
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An In silico Investigation to Identify Promising Inhibitors for SARS-CoV-2 M
    Alagarsamy V; Sundar PS; Narendhar B; Sulthana MT; Kulkarni VS; Aishwarya AD; Solomon VR; Murugesan S; Jubie S; Rohitha K; Dhanwar S
    Med Chem; 2023; 19(9):925-938. PubMed ID: 37069723
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.
    Li K; Meyerholz DK; Bartlett JA; McCray PB
    mBio; 2021 Aug; 12(4):e0097021. PubMed ID: 34340553
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Strong Binding of Leupeptin with TMPRSS2 Protease May Be an Alternative to Camostat and Nafamostat for SARS-CoV-2 Repurposed Drug: Evaluation from Molecular Docking and Molecular Dynamics Simulations.
    Ramakrishnan J; Kandasamy S; Iruthayaraj A; Magudeeswaran S; Chinnasamy K; Poomani K
    Appl Biochem Biotechnol; 2021 Jun; 193(6):1909-1923. PubMed ID: 33512650
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In-silico screening for identification of potential inhibitors against SARS-CoV-2 transmembrane serine protease 2 (TMPRSS2).
    Barge S; Jade D; Gosavi G; Talukdar NC; Borah J
    Eur J Pharm Sci; 2021 Jul; 162():105820. PubMed ID: 33775827
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phytoconstituents from ten natural herbs as potent inhibitors of main protease enzyme of SARS-COV-2:
    Kumar N; Singh A; Gulati HK; Bhagat K; Kaur K; Kaur J; Dudhal S; Duggal A; Gulati P; Singh H; Singh JV; Bedi PMS
    Phytomed Plus; 2021 Nov; 1(4):100083. PubMed ID: 35403086
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In silico study of alkaloids with quercetin nucleus for inhibition of SARS-CoV-2 protease and receptor cell protease.
    Mohebbi A; Eskandarzadeh M; Zangi H; Fatehi M
    PLoS One; 2024; 19(4):e0298201. PubMed ID: 38626042
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Computational Evidences of Phytochemical Mediated Disruption of PLpro Driven Replication of SARS-CoV-2: A Therapeutic Approach against COVID-19.
    Balkrishna A; Mittal R; Arya V
    Curr Pharm Biotechnol; 2021; 22(10):1350-1359. PubMed ID: 33176643
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of potential anti-TMPRSS2 natural products through homology modelling, virtual screening and molecular dynamics simulation studies.
    Chikhale RV; Gupta VK; Eldesoky GE; Wabaidur SM; Patil SA; Islam MA
    J Biomol Struct Dyn; 2020 Aug; ():1-16. PubMed ID: 32741259
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification, virtual screening and molecular dynamic analysis of novel TMPRSS2 inhibitors from natural compound database as potential entry-blocking agents in SARS-CoV-2 therapy.
    Manandhar S; Pai KSR; Krishnamurthy PT; Kiran AVVVR; Kumari GK
    Struct Chem; 2022; 33(5):1609-1617. PubMed ID: 35754942
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structural insights and inhibition mechanism of TMPRSS2 by experimentally known inhibitors Camostat mesylate, Nafamostat and Bromhexine hydrochloride to control SARS-coronavirus-2: A molecular modeling approach.
    Sonawane KD; Barale SS; Dhanavade MJ; Waghmare SR; Nadaf NH; Kamble SA; Mohammed AA; Makandar AM; Fandilolu PM; Dound AS; Naik NM; More VB
    Inform Med Unlocked; 2021; 24():100597. PubMed ID: 34075338
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Computational screening of camostat and related compounds against human TMPRSS2: A potential treatment of COVID-19.
    Sharma T; Baig MH; Khan MI; Alotaibi SS; Alorabi M; Dong JJ
    Saudi Pharm J; 2022 Mar; 30(3):217-224. PubMed ID: 35095307
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    Lawal B; Tsai SK; Wu ATH; Huang HS
    Arab J Chem; 2023 May; 16(5):104654. PubMed ID: 36777994
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The discovery and development of transmembrane serine protease 2 (TMPRSS2) inhibitors as candidate drugs for the treatment of COVID-19.
    Mantzourani C; Vasilakaki S; Gerogianni VE; Kokotos G
    Expert Opin Drug Discov; 2022 Mar; 17(3):231-246. PubMed ID: 35072549
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synergistic Block of SARS-CoV-2 Infection by Combined Drug Inhibition of the Host Entry Factors PIKfyve Kinase and TMPRSS2 Protease.
    Kreutzberger AJB; Sanyal A; Ojha R; Pyle JD; Vapalahti O; Balistreri G; Kirchhausen T
    J Virol; 2021 Oct; 95(21):e0097521. PubMed ID: 34406858
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.